Table 2.
Maintenance dose of warfarin by EPHX1 SNPs, stratified by race
| SNP | Major allele (A) | Minor allele (B) | AA (n) | AB (n) | BB (n) | AA Median dose (min−max) | AB Median dose (min−max) | BB Median dose (min−max) | P value* | Partial R2* |
|---|---|---|---|---|---|---|---|---|---|---|
| African American | ||||||||||
| rs1877724 | C | T | 18 | 4 | 0 | 46.25 (10.00–80.00) | 35.00 (27.50–45.00) | – | 0.66 | 0.01 |
| rs3766934 | G | T | 16 | 5 | 1 | 36.25 (25.00–80.00) | 45.00 (10.00–55.00) | 67.50 | 0.99 | <0.001 |
| rs2671272 | G | A | 8 | 10 | 4 | 45.00 (32.50–67.50) | 35.00 (10.00–80.00) | 38.13 (25.00–52.50) | 0.35 | 0.05 |
| rs2234697 | C | T | 13 | 5 | 0 | 45.00 (10.00–80.00) | 35.00 (25.00–52.50) | – | 0.71 | 0.01 |
| rs1051740 | T | C | 13 | 5 | 1 | 47.50 (10.00–80.00) | 35.00 (25.00–52.50) | 45.00 | 0.95 | <0.001 |
| rs2292566 | G | A | 20 | 1 | 1 | 41.25 (10.00–80.00) | 47.50 | 26.25 | 0.53 | 0.02 |
| rs2260863 | C | G | 10 | 8 | 4 | 33.75 (25.00–80.00) | 50.00 (32.50–62.50) | 31.88 (10.00–50.00) | 0.25 | 0.07 |
| rs2740168 | G | A | 10 | 7 | 5 | 33.75 (10.00–67.50) | 47.50 (30.00–80.00) | 35.00 (25.00–47.50) | 0.53 | 0.02 |
| rs10915884 | C | T | 17 | 5 | 0 | 37.50 (10.00–67.50) | 45.00 (35.00–80.00) | – | 0.27 | 0.07 |
| rs2740170 | C | T | 17 | 5 | 0 | 45.00 (25.00–80.00) | 35.00 (10.00–55.00) | 0.16 | 0.11 | |
| rs2740171 | C | A | 9 | 12 | 1 | 47.50 (27.50–80.00) | 36.25 (10.00–67.50) | 26.25 | 0.12 | 0.14 |
| rs2234922 | A | G | 10 | 8 | 3 | 41.25 (25.00–67.50) | 41.25 (10.00–80.00) | 32.50 (26.25–52.50) | 0.62 | 0.02 |
| rs1051741 | C | T | 18 | 4 | 0 | 36.25 (10.00–80.00) | 52.50 (35.00–62.50) | – | 0.18 | 0.10 |
| rs4149229 | G | A | 18 | 4 | 0 | 41.25 (10.00–62.50) | 47.50 (25.00–80.00) | – | 0.64 | 0.01 |
| Caucasian | ||||||||||
| rs1877724 | C | T | 20 | 12 | 3 | 41.88 (17.50–95.00) | 33.75 (17.50–80.00) | 36.00 (26.00–40.00) | 0.25 | 0.02 |
| rs3766934 | G | T | 29 | 7 | 0 | 37.50 (17.50–95.00) | 42.00 (23.00–63.75) | – | 0.87 | <0.001 |
| rs2671272 | G | A | 21 | 12 | 3 | 40.00 (17.50–95.00) | 28.75 (17.50–56.25) | 45.00 (35.00–50.00) | 0.45 | 0.01 |
| rs2234697 | C | T | 23 | 4 | 1 | 30.00 (17.50–95.00) | 65.00 (40.00–80.00) | 42.50 | 0.40 | 0.02 |
| rs1051740 | T | C | 12 | 15 | 3 | 35.50 (17.50–63.75) | 52.50 (20.00–95.00) | 30.00 (25.00–42.00) | 0.12 | 0.05 |
| rs2292566 | G | A | 27 | 9 | 0 | 37.50 (17.50–95.00) | 55.00 (17.50–80.00) | – | 0.82 | 0.001 |
| rs2260863 | C | G | 21 | 5 | 9 | 40.00 (17.50–95.00) | 27.50 (17.50–56.25) | 42.50 (23.00–63.75) | † | † |
| rs2740168 | G | A | 15 | 15 | 5 | 41.25 (17.50–63.75) | 30.00 (17.50–95.00) | 35.00 (20.00–80.00) | 0.64 | 0.005 |
| rs10915884 | C | T | 22 | 13 | 1 | 38.75 (17.50–95.00) | 30.00 (20.00–75.00) | 80.00 | 0.92 | <0.001 |
| rs2740170 | C | T | 22 | 9 | 4 | 38.75 (17.50–95.00) | 27.50 (17.50–56.25) | 47.50 (25.50–63.75) | 0.97 | <0.001 |
| rs2740171 | C | A | 21 | 11 | 4 | 37.50 (17.50–95.00) | 30.00 (17.50–56.25) | 47.50 (25.50–63.75) | 0.61 | 0.01 |
| rs2234922 | A | G | 21 | 12 | 2 | 40.00 (17.50–80.00) | 36.25 (17.50–95.00) | 30.00 (25.00–35.00) | 0.62 | 0.01 |
| rs1051741 | C | T | 29 | 7 | 0 | 41.25 (17.50–95.00) | 30.00 (17.50–42.50) | – | 0.04 | 0.08 |
| rs4149229 | G | A | 35 | 1 | 0 | 37.50 (17.50–95.00) | 42.50 | – | – | – |
*
The relationship between each SNP and log-transformed maintenance dose was adjusted for the VKORC1 1173C>T and CYP2C9 *2 and *3 variants.
†
SNP was not in Hardy–Weinberg equilibrium (P < 0.0001).